ofloxacin has been researched along with Cross Infection in 74 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Cross Infection: Any infection which a patient contracts in a health-care institution.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy." | 9.11 | Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004) |
| "A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)." | 7.74 | A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. ( Dowzicky, M; Kuti, JL; Nicolau, DP, 2008) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 7.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 7.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| " Its improved bioavailability and safety profile makes the possibility of shorter hospital stays a reality." | 6.48 | Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012) |
| " Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX." | 5.40 | [Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia]. ( Akata, K; Awaya, Y; Chojin, Y; Hara, K; Hata, R; Inoue, N; Ishimoto, H; Kato, K; Kawanami, T; Kawanami, Y; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Obata, H; Oda, K; Ogoshi, T; Orihashi, T; Sasahara, Y; Shimabukuro, I; Shiraishi, T; Suzuki, Y; Tachiwada, T; Takaki, T; Taura, Y; Tokuyama, S; Tsuda, T; Uchimura, K; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2014) |
| "An analysis of subjects with concurrent bacteraemia and either nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection from six phase 3 clinical trials demonstrated similar cure rates and clearance of bacteraemia in patients treated with doripenem and comparator agents." | 5.17 | Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials. ( Kaniga, K; Lee, M; Redman, R; Rice, DA, 2013) |
| "An open-label randomised clinical trial was designed to compare the efficacy and tolerance of levofloxacin and ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with high-risk neutropenia, and to monitor the emergence of antimicrobial resistance." | 5.12 | Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies. ( Huijgens, PC; Janssen, JJ; Leidekker, ME; Simoons-Smit, AM; Timmers, GJ; Vandenbroucke-Grauls, CM, 2007) |
| "In this study, we analyzed 302 patients with pneumonia admitted to the Intensive Care Unit (ICU) who were treated with levofloxacin (LFX) either as monotherapy or combined therapy." | 5.11 | Levofloxacin in the treatment of pneumonia in intensive care unit patients. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sanchez, M, 2004) |
| "In a multicentre non-randomized open prospective study, 124 patients hospitalized in medical infectious disease or intensive care units, with severe community and hospital-acquired bacterial infections were treated with 15 mg/kg body weight amikacin in a once-daily dose given as a 30 min iv infusion, combined with other antibiotics." | 5.07 | Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. ( Beaucaire, G; Beuscart, C; Caillaux, M; Chidiac, C; Karp, P; Leroy, O, 1991) |
| "The efficacy and safety of ofloxacin for the treatment of pneumonia, urinary infection and skin infections in the institutionalized elderly is being studied in a multicenter North American trial." | 5.07 | Ofloxacin use in a geriatric population. ( Alessi, P; Cullison, J; Degelau, J; Meyers, B; Nicolle, LE, 1991) |
| "Strains isolated in health-related bacteriuria are more frequently ofloxacin resistant principally because of the greater proportion of Gram positive bacteria and because of a non-significant higher ofloxacin resistance rate among Enterobacteriaceae." | 3.78 | [Differences between species involved and fluoroquinolone resistance patterns of strains isolated from bacteriuria according to nosocomial, health-related or community-acquired onset]. ( Batalla, AS; De Champs, C; Duval, V; Guillard, T; N'Guyen, Y; Strady, C; Tassain, J, 2012) |
| "Among hospitalized patients with diarrhea who underwent testing for C difficile toxin, age 75 years or older, hospitalization for 7 days or greater, and recent exposure to cefazolin or levofloxacin were important predictors of a positive CDTT." | 3.74 | Is it Clostridium difficile infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea. ( Aradhyula, S; Greisnauer, S; Manian, FA; Meyer, PL; Senkel, D; Setzer, J; Wiechens, M, 2007) |
| "A pharmacodynamic model was used to generate supportive data comparing tigecycline with other broad-spectrum agents against pathogens implicated in hospital-acquired pneumonia (HAP)." | 3.74 | A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. ( Dowzicky, M; Kuti, JL; Nicolau, DP, 2008) |
| "We report a multicentric, open trial of intravenous followed by oral ofloxacin, 400 mg every 12 h, as therapy for 100 cases of nosocomial pneumonia and community-acquired pneumonia requiring hospitalization." | 3.68 | Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization. ( Gentry, LO; Khan, FA; Kohler, RB; Rodriguez-Gomez, G; Rytel, MW, 1992) |
| "In order to determine the efficacy and safety of the new quinolone ofloxacin in the treatment of chronic lower respiratory disease, 674 patients (353 with chronic bronchitis, 212 with community-acquired pneumonia and 109 with hospital-acquired pneumonia) were treated with ofloxacin 200 mg twice a day." | 3.68 | Ofloxacin in lower respiratory tract infections. ( Petermann, W, 1991) |
| "The minimal inhibitory concentrations (MIC) of ofloxacin against 400 isolates cultured from the urine of urological patients with complicated urinary tract infections (UTI) resulted in an inhibition of 94% (99%) of the gram-negative strains at a concentration of 1 mg/l (2 mg/l) and an inhibition of 59% (100%) of the gram-positive strains at a concentration of 1 mg/l (4 mg/l)." | 3.67 | [In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections]. ( Adam, D; Bartosik-Wich, B; Naber, KG; Wittenberger, R, 1986) |
| "42 mL/min/kg]), leading to a shorter elimination half-life (5." | 2.71 | Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ( Baldassarre, M; Brollo, L; Cusenza, A; Di Qual, E; Furlanut, M; Pea, F, 2003) |
| "Levofloxacin was administered as an infusion of 500 mg/h for 1." | 2.71 | Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. ( Corrado, M; Drusano, GL; Fowler, C; Kahn, J; Preston, SL; Weisinger, B, 2004) |
| "Fifteen patients with severe hospital infections such as postoperative pneumonia or intraabdominal sepsis were treated with ofloxacin in a dose of 400 mg once a day for 7 to 14 days (11 days at the average)." | 2.68 | [Clinical trials of ofloxacin in sequential use (intravenous and oral) in patients with serious hospital infection]. ( Dvoretskiĭ, LI; Eremina, LV; Iakovlev, SV; Kudinkina, IP; Prokhorenko, TS; Shakhova, TV; Vlasenko, NA; Vorob'ev, PA, 1996) |
| " Its improved bioavailability and safety profile makes the possibility of shorter hospital stays a reality." | 2.48 | Levofloxacin for the treatment of respiratory tract infections. ( Liapikou, A; Torres, A, 2012) |
| "Clinical manifestations of Legionnaires' disease are not specific and current diagnostic scores are of limited use." | 2.46 | An update on Legionella. ( Carratalà, J; Garcia-Vidal, C, 2010) |
| "For levofloxacin-treated CAP patients with P." | 2.43 | Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience. ( Davis, NB; Kahn, J; Tennenberg, AM; Wu, SC, 2006) |
| " Pharmacodynamic principles can also be used to devise the optimal administration regimen for specific antimicrobial agents." | 2.41 | Pharmacodynamics and pharmacokinetics of levofloxacin. ( Grant, EM; Nightingale, CH; Quintiliani, R, 2000) |
| "The empiric treatment of acute pyelonephritis (APN) with third generation cephalosporins (3GC) or fluoroquinolones (FQ) has been challenged by Escherichia coli resistance reported by community surveillance networks." | 1.40 | Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors. ( Caron, F; Choplin-Renard, J; Etienne, M; Pestel-Caron, M; Van Elslande, H, 2014) |
| " Nine patients (2 with liver dysfunction, 6 with renal dysfunction and 1 with thrombocytopenia) out of 62 patients were reported to have possible adverse effects of LVFX." | 1.40 | [Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia]. ( Akata, K; Awaya, Y; Chojin, Y; Hara, K; Hata, R; Inoue, N; Ishimoto, H; Kato, K; Kawanami, T; Kawanami, Y; Mukae, H; Naito, K; Nishida, C; Noguchi, S; Obata, H; Oda, K; Ogoshi, T; Orihashi, T; Sasahara, Y; Shimabukuro, I; Shiraishi, T; Suzuki, Y; Tachiwada, T; Takaki, T; Taura, Y; Tokuyama, S; Tsuda, T; Uchimura, K; Yamasaki, K; Yatera, K; Yoshida, Y; Yoshii, C, 2014) |
| "A 55 year-old male patient with chronic renal failure was hospitalized in intensive care unit following cardiopulmonary arrest." | 1.38 | [A case of ventilator-associated pneumonia due to Pantoea agglomerans]. ( Altın, N; Argun, C; Canbakan, B; Cesur, S; Koldaş, K; Kurşun, O; Sencan, I; Unal, N, 2012) |
| "Levofloxacin use was associated with increased resistance of P." | 1.36 | Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use. ( Chun, CL; Hsueh, PR; Lee, YJ; Lin, YC; Liu, HY; Sun, KL, 2010) |
| "This report describes an outbreak of Legionnaires' disease in severely immunosuppressed patients hospitalised at a cancer centre." | 1.34 | Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy. ( Angeles Domínguez, M; Carratalà, J; Fernández-Sevilla, A; Gudiol, C; Verdaguer, R, 2007) |
| "Levofloxacin was added to the formulary in 1999, and gatifloxacin was substituted for levofloxacin in 2001." | 1.33 | Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. ( Bosso, JA; Mauldin, PD, 2006) |
| "Levofloxacin use was more frequent in the QR P." | 1.33 | Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa. ( Carmeli, Y; Dodds, AE; Engemann, JJ; Kanafani, ZA; Kaye, KS; Weber, SG, 2006) |
| "Pseudomonas aeruginosa infections have been associated with considerable morbidity and mortality." | 1.33 | Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. ( Bilker, WB; Fishman, NO; Gasink, LB; Lautenbach, E; Nachamkin, I; Weiner, MG, 2006) |
| "Levofloxacin is a new, recently commercialized fluoroquinolone." | 1.32 | [Use of levofloxacin in the hospital]. ( Arnau, JM; Campany, D; Castells, X; Rigau, D; Vallano, A, 2003) |
| "Levofloxacin was predominantly prescribed for treating community-acquired infections (67." | 1.32 | [Observational study investigating the use of levofloxacin in ICU patients]. ( Alvarez-Lerma, F; Bermejo, B; León, C; Olaechea, P; Palomar, M; Sánchez, M, 2004) |
| "Ciprofloxacin was the quinolone of choice in 24/32 (75%) of assessable cases." | 1.29 | An audit of ciprofloxacin use in a district general hospital. ( Fenelon, LE; MacGowan, AP; Reeves, DS; Smyth, EG; Speirs, GE; Speller, DC; Wilcox, MH, 1995) |
| "Among 219 pathogens originating from nosocomial infections, 3." | 1.27 | Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.05) | 18.7374 |
| 1990's | 14 (18.92) | 18.2507 |
| 2000's | 45 (60.81) | 29.6817 |
| 2010's | 11 (14.86) | 24.3611 |
| 2020's | 1 (1.35) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, N | 1 |
| Leitão, J | 1 |
| Manageiro, V | 1 |
| Ferreira, E | 1 |
| Caniça, M | 1 |
| Gutiérrez, O | 1 |
| Juan, C | 1 |
| Cercenado, E | 1 |
| Navarro, F | 1 |
| Bouza, E | 1 |
| Coll, P | 1 |
| Pérez, JL | 1 |
| Oliver, A | 1 |
| Quiroga, MP | 1 |
| Andres, P | 1 |
| Petroni, A | 1 |
| Soler Bistué, AJ | 1 |
| Guerriero, L | 1 |
| Vargas, LJ | 1 |
| Zorreguieta, A | 1 |
| Tokumoto, M | 1 |
| Quiroga, C | 1 |
| Tolmasky, ME | 1 |
| Galas, M | 1 |
| Centrón, D | 1 |
| Carrër, A | 1 |
| Poirel, L | 1 |
| Eraksoy, H | 1 |
| Cagatay, AA | 1 |
| Badur, S | 1 |
| Nordmann, P | 1 |
| Lecuru, M | 1 |
| Daniau, C | 1 |
| Alfandari, S | 1 |
| Dumartin, C | 1 |
| Bajolet, O | 1 |
| Blanchard, H | 1 |
| Simon, L | 1 |
| Colomb-Cotinat, M | 1 |
| Rice, DA | 1 |
| Kaniga, K | 1 |
| Lee, M | 1 |
| Redman, R | 1 |
| Etienne, M | 1 |
| Van Elslande, H | 1 |
| Choplin-Renard, J | 1 |
| Pestel-Caron, M | 1 |
| Caron, F | 1 |
| Yamasaki, K | 1 |
| Yatera, K | 1 |
| Kawanami, T | 1 |
| Sasahara, Y | 1 |
| Hata, R | 1 |
| Uchimura, K | 1 |
| Tachiwada, T | 1 |
| Naito, K | 1 |
| Kato, K | 1 |
| Takaki, T | 1 |
| Shimabukuro, I | 1 |
| Shiraishi, T | 1 |
| Oda, K | 1 |
| Hara, K | 1 |
| Chojin, Y | 1 |
| Suzuki, Y | 1 |
| Akata, K | 1 |
| Ogoshi, T | 1 |
| Tokuyama, S | 1 |
| Inoue, N | 1 |
| Noguchi, S | 1 |
| Nishida, C | 1 |
| Orihashi, T | 1 |
| Yoshida, Y | 1 |
| Kawanami, Y | 1 |
| Taura, Y | 1 |
| Ishimoto, H | 1 |
| Obata, H | 1 |
| Awaya, Y | 1 |
| Tsuda, T | 1 |
| Yoshii, C | 1 |
| Mukae, H | 1 |
| Blatun, LA | 1 |
| Terekhova, RP | 1 |
| Alvarez Lerma, F | 1 |
| Romero Luján, JL | 1 |
| Morón Jiménez, A | 1 |
| Ortiz López, R | 1 |
| Borges Sá, M | 1 |
| Grau Cerrato, S | 1 |
| Gracia Arnillas, MP | 1 |
| Cox, HS | 1 |
| Sibilia, K | 1 |
| Feuerriegel, S | 1 |
| Kalon, S | 1 |
| Polonsky, J | 1 |
| Khamraev, AK | 1 |
| Rüsch-Gerdes, S | 1 |
| Mills, C | 1 |
| Niemann, S | 1 |
| Passerini de Rossi, B | 1 |
| García, C | 1 |
| Calenda, M | 1 |
| Vay, C | 1 |
| Franco, M | 1 |
| Riabkova, EL | 1 |
| Kozlov, RS | 1 |
| Beloborodov, VB | 1 |
| Hosgor-Limoncu, M | 1 |
| Ermertcan, S | 1 |
| Tasli, H | 1 |
| Yurtman, AN | 1 |
| Lee, YJ | 1 |
| Liu, HY | 1 |
| Lin, YC | 1 |
| Sun, KL | 1 |
| Chun, CL | 1 |
| Hsueh, PR | 2 |
| Carratalà, J | 2 |
| Garcia-Vidal, C | 1 |
| Blasi, F | 1 |
| Petrosillo, N | 1 |
| Khawcharoenporn, T | 1 |
| Vasoo, S | 1 |
| Ward, E | 1 |
| Singh, K | 1 |
| Elgorriaga-Islas, E | 1 |
| Guggiana-Nilo, P | 1 |
| Domínguez-Yévenes, M | 1 |
| González-Rocha, G | 1 |
| Mella-Montecinos, S | 1 |
| Labarca-Labarca, J | 1 |
| García-Cañete, P | 1 |
| Bello-Toledo, H | 1 |
| Torres, A | 1 |
| Liapikou, A | 1 |
| Kurşun, O | 1 |
| Unal, N | 1 |
| Cesur, S | 1 |
| Altın, N | 1 |
| Canbakan, B | 1 |
| Argun, C | 1 |
| Koldaş, K | 1 |
| Sencan, I | 1 |
| Tassain, J | 1 |
| N'Guyen, Y | 1 |
| Batalla, AS | 1 |
| Duval, V | 1 |
| Guillard, T | 1 |
| De Champs, C | 1 |
| Strady, C | 1 |
| West, M | 1 |
| Boulanger, BR | 1 |
| Fogarty, C | 1 |
| Tennenberg, A | 1 |
| Wiesinger, B | 1 |
| Oross, M | 1 |
| Wu, SC | 3 |
| Fowler, C | 2 |
| Morgan, N | 1 |
| Kahn, JB | 1 |
| Pea, F | 1 |
| Di Qual, E | 1 |
| Cusenza, A | 1 |
| Brollo, L | 1 |
| Baldassarre, M | 1 |
| Furlanut, M | 1 |
| Castells, X | 1 |
| Vallano, A | 1 |
| Campany, D | 1 |
| Rigau, D | 1 |
| Arnau, JM | 1 |
| Gaynes, R | 1 |
| Rimland, D | 1 |
| Killum, E | 1 |
| Lowery, HK | 1 |
| Johnson, TM | 1 |
| Killgore, G | 2 |
| Tenover, FC | 2 |
| Alvarez-Lerma, F | 3 |
| Palomar, M | 2 |
| Olaechea, P | 2 |
| León, C | 2 |
| Sánchez, M | 2 |
| Bermejo, B | 2 |
| Drusano, GL | 1 |
| Preston, SL | 1 |
| Corrado, M | 1 |
| Weisinger, B | 1 |
| Kahn, J | 2 |
| Naber, KG | 2 |
| Viale, P | 1 |
| Scudeller, L | 1 |
| Cristini, F | 1 |
| Shorr, AF | 2 |
| Susla, GB | 1 |
| Kollef, MH | 2 |
| Zadeikis, N | 1 |
| Jackson, WL | 1 |
| Ramage, AS | 1 |
| Tennenberg, AM | 2 |
| Lanzafame, A | 1 |
| Bonfiglio, G | 1 |
| Santini, L | 1 |
| Mattina, R | 1 |
| Muto, CA | 1 |
| Pokrywka, M | 1 |
| Shutt, K | 1 |
| Mendelsohn, AB | 1 |
| Nouri, K | 1 |
| Posey, K | 1 |
| Roberts, T | 1 |
| Croyle, K | 1 |
| Krystofiak, S | 1 |
| Patel-Brown, S | 1 |
| Pasculle, AW | 1 |
| Paterson, DL | 1 |
| Saul, M | 1 |
| Harrison, LH | 1 |
| Chen, WH | 1 |
| Luh, KT | 1 |
| Grau, S | 1 |
| Alvarez-Beltrán, M | 1 |
| Davis, NB | 1 |
| Bosso, JA | 1 |
| Mauldin, PD | 1 |
| Kaye, KS | 1 |
| Kanafani, ZA | 1 |
| Dodds, AE | 1 |
| Engemann, JJ | 1 |
| Weber, SG | 1 |
| Carmeli, Y | 1 |
| Gasink, LB | 1 |
| Fishman, NO | 1 |
| Weiner, MG | 1 |
| Nachamkin, I | 1 |
| Bilker, WB | 1 |
| Lautenbach, E | 1 |
| Bassetti, M | 1 |
| Righi, E | 1 |
| Rosso, R | 1 |
| Mannelli, S | 1 |
| Di Biagio, A | 1 |
| Fasce, R | 1 |
| Pallavicini, FB | 1 |
| Marchetti, F | 1 |
| Viscoli, C | 1 |
| Sirvent, E | 1 |
| Ruiz, M | 1 |
| Rodríguez, JC | 1 |
| Royo, G | 1 |
| Timmers, GJ | 1 |
| Simoons-Smit, AM | 1 |
| Leidekker, ME | 1 |
| Janssen, JJ | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Huijgens, PC | 1 |
| Biller, P | 1 |
| Shank, B | 1 |
| Lind, L | 1 |
| Brennan, M | 1 |
| Tkatch, L | 1 |
| Thompson, A | 1 |
| McDonald, LC | 1 |
| Gudiol, C | 1 |
| Verdaguer, R | 1 |
| Angeles Domínguez, M | 1 |
| Fernández-Sevilla, A | 1 |
| Manian, FA | 1 |
| Aradhyula, S | 1 |
| Greisnauer, S | 1 |
| Senkel, D | 1 |
| Setzer, J | 1 |
| Wiechens, M | 1 |
| Meyer, PL | 1 |
| Kuti, JL | 1 |
| Dowzicky, M | 1 |
| Nicolau, DP | 1 |
| von Gottberg, A | 1 |
| Klugman, KP | 1 |
| Cohen, C | 1 |
| Wolter, N | 1 |
| de Gouveia, L | 1 |
| du Plessis, M | 1 |
| Mpembe, R | 1 |
| Quan, V | 1 |
| Whitelaw, A | 1 |
| Hoffmann, R | 1 |
| Govender, N | 1 |
| Meiring, S | 1 |
| Smith, AM | 1 |
| Schrag, S | 1 |
| Wang, A | 1 |
| Yang, Y | 1 |
| Lu, Q | 1 |
| Wang, Y | 1 |
| Chen, Y | 1 |
| Deng, L | 1 |
| Ding, H | 1 |
| Deng, Q | 1 |
| Wang, L | 1 |
| Shen, X | 1 |
| Trzciński, K | 1 |
| Zareba, T | 1 |
| Tyski, S | 1 |
| Hryniewicz, W | 1 |
| Beam, TR | 1 |
| Kern, WV | 1 |
| Andriof, E | 1 |
| Oethinger, M | 1 |
| Kern, P | 1 |
| Hacker, J | 1 |
| Marre, R | 1 |
| Speirs, GE | 1 |
| Fenelon, LE | 1 |
| Reeves, DS | 1 |
| Speller, DC | 1 |
| Smyth, EG | 1 |
| Wilcox, MH | 1 |
| MacGowan, AP | 1 |
| Stein, GE | 1 |
| Molinari, G | 1 |
| Schito, GC | 1 |
| Iakovlev, SV | 1 |
| Dvoretskiĭ, LI | 1 |
| Shakhova, TV | 1 |
| Kudinkina, IP | 1 |
| Vorob'ev, PA | 1 |
| Vlasenko, NA | 1 |
| Prokhorenko, TS | 1 |
| Eremina, LV | 1 |
| Tabe, Y | 1 |
| Nakamura, A | 1 |
| Oguri, T | 1 |
| Igari, J | 1 |
| Scotton, PG | 1 |
| Tonon, E | 1 |
| Giobbia, M | 1 |
| Gallucci, M | 1 |
| Rigoli, R | 1 |
| Vaglia, A | 1 |
| Nightingale, CH | 1 |
| Grant, EM | 1 |
| Quintiliani, R | 1 |
| Steward, CD | 1 |
| Wallace, D | 1 |
| Hubert, SK | 1 |
| Lawton, R | 1 |
| Fridkin, SK | 1 |
| Gaynes, RP | 1 |
| McGowan, JE | 1 |
| Dreyfuss, D | 1 |
| Mier, L | 1 |
| Graffunder, EM | 1 |
| Venezia, RA | 1 |
| Gür, D | 1 |
| Kocagöz, T | 1 |
| Akalin, HE | 1 |
| Gentry, LO | 1 |
| Rodriguez-Gomez, G | 1 |
| Kohler, RB | 1 |
| Khan, FA | 1 |
| Rytel, MW | 1 |
| Petermann, W | 1 |
| Beaucaire, G | 1 |
| Leroy, O | 1 |
| Beuscart, C | 1 |
| Karp, P | 1 |
| Chidiac, C | 1 |
| Caillaux, M | 1 |
| Nicolle, LE | 1 |
| Degelau, J | 1 |
| Alessi, P | 1 |
| Cullison, J | 1 |
| Meyers, B | 1 |
| Carbon, C | 1 |
| Delval, C | 1 |
| Adam, D | 1 |
| Wittenberger, R | 1 |
| Bartosik-Wich, B | 1 |
| Kosakai, N | 1 |
| Rubinstein, E | 1 |
| Mark, Z | 1 |
| Keren, G | 1 |
| Alkan, M | 1 |
| Berger, S | 1 |
| Bogokowski, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia[NCT00236834] | Phase 3 | 438 participants (Actual) | Interventional | 1997-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for ofloxacin and Cross Infection
| Article | Year |
|---|---|
[Present aspects and prospects of levofloxacin use in therapy of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
[Clinical positioning of levofloxacin in the treatment of nosocomial pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Levofloxacin; Ofloxacin; Pneumonia, Bacterial | 2008 |
An update on Legionella.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Azithromycin; Community-Acquired Infections; Cross Infec | 2010 |
[Therapeutic experience with levofloxacin in pneumonia and COPD].
Topics: Algorithms; Anti-Bacterial Agents; Clinical Trials as Topic; Community-Acquired Infections; Cross In | 2009 |
Levofloxacin for the treatment of respiratory tract infections.
Topics: Anti-Bacterial Agents; Community-Acquired Infections; Cross Infection; Humans; Levofloxacin; Ofloxac | 2012 |
Levofloxacin in the treatment of urinary tract infections and prostatitis.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug | 2004 |
Quinolones for treatment of nosocomial pneumonia: a meta-analysis.
Topics: Anti-Infective Agents; Cilastatin; Ciprofloxacin; Cross Infection; Humans; Imipenem; Levofloxacin; M | 2005 |
Levofloxacin in the treatment of ventilator-associated pneumonia.
Topics: Anti-Infective Agents; Cross Infection; Gram-Negative Bacterial Infections; Humans; Levofloxacin; Of | 2006 |
Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
Topics: Adult; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Re | 2006 |
Quinolone therapy in intensive care unit settings.
Topics: Administration, Oral; Aged; Ciprofloxacin; Clinical Protocols; Clinical Trials as Topic; Cross Infec | 1993 |
Pharmacodynamics and pharmacokinetics of levofloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Cost-Benefit Analysis; Cross Infection; Drug Costs; Humans; | 2000 |
12 trials available for ofloxacin and Cross Infection
| Article | Year |
|---|---|
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Topics: Anti-Bacterial Agents; Bacteremia; Carbapenems; Cross Infection; Doripenem; Female; Humans; Imipenem | 2013 |
Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study.
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Ciprofloxacin; Cross Infection; Drug Therapy, Combin | 2003 |
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia.
Topics: Aged; Anti-Infective Agents; Chromatography, High Pressure Liquid; Critical Illness; Cross Infection | 2003 |
Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Area Under Curve; Cross Infection; Female; Fl | 2004 |
Levofloxacin in the treatment of pneumonia in intensive care unit patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Critical Illness; Cross Infection | 2004 |
Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial.
Topics: Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Cohort Studies; Cross Infe | 2005 |
Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Cross Infection; Drug Therapy, Combination; Female; Gram-N | 2006 |
Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Cross Infecti | 2007 |
[Clinical trials of ofloxacin in sequential use (intravenous and oral) in patients with serious hospital infection].
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Cross Infection; Drug Administration Sched | 1996 |
Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections.
Topics: Adult; Aged; Amikacin; Bacterial Infections; Cefotaxime; Ceftazidime; Cross Infection; Drug Administ | 1991 |
Ofloxacin use in a geriatric population.
Topics: Aged; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Ofloxacin; Pneumonia; | 1991 |
[Therapeutic potential of ofloxacin in hospital medicine. A French multicenter study].
Topics: Bacteria, Anaerobic; Cross Infection; Drug Resistance, Microbial; Gram-Negative Bacteria; Gram-Posit | 1990 |
51 other studies available for ofloxacin and Cross Infection
| Article | Year |
|---|---|
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R | 2007 |
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactama | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross I | 2007 |
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
Topics: Bacterial Proteins; beta-Lactamases; Carbapenems; Cross Infection; Drug Resistance, Bacterial; Elect | 2008 |
Evolution of antibiotic treatments for healthcare-associated infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in France.
Topics: Aminoglycosides; Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Carbapenems; Cla | 2022 |
Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Catchment Area, Heal | 2014 |
[Efficacy and safety of levofloxacin in patients with nursing and healthcare-associated pneumonia].
Topics: Anti-Bacterial Agents; Cross Infection; Female; Humans; Japan; Levofloxacin; Male; Ofloxacin; Pneumo | 2014 |
[Oflomelid ointment: activity against hospital microbial strains].
Topics: Acinetobacter; Anti-Bacterial Agents; Cross Infection; Disk Diffusion Antimicrobial Tests; Escherich | 2014 |
[Levofloxacin in the treatment of nosocomial infection in critically ill patients].
Topics: Anti-Bacterial Agents; Critical Illness; Cross Infection; Female; Humans; Levofloxacin; Male; Middle | 2008 |
Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis.
Topics: Analysis of Variance; Antitubercular Agents; Cross Infection; Extensively Drug-Resistant Tuberculosi | 2008 |
Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections.
Topics: Anti-Infective Agents; Argentina; Biofilms; Ciprofloxacin; Cross Infection; Drug Resistance, Multipl | 2009 |
Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cross Infection; Drug Synergism; Drug | 2008 |
Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Bacterial; Drug Utilization; | 2010 |
[Experience accumulated in hospital setting with levofloxacin, in monotherapy and in association therapy].
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Community-Acquired Infect | 2009 |
High rates of quinolone resistance among urinary tract infections in the ED.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents | 2012 |
[Prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr among ESBL producing enterobacteria isolates from Chilean hospitals].
Topics: Acetylation; Anti-Bacterial Agents; Bacterial Proteins; Chile; Ciprofloxacin; Cross Infection; Drug | 2012 |
[A case of ventilator-associated pneumonia due to Pantoea agglomerans].
Topics: Anti-Bacterial Agents; Cefoperazone; Cross Infection; Drug Therapy, Combination; Enterobacteriaceae | 2012 |
[Differences between species involved and fluoroquinolone resistance patterns of strains isolated from bacteriuria according to nosocomial, health-related or community-acquired onset].
Topics: Anti-Bacterial Agents; Bacteriuria; Community-Acquired Infections; Cross Infection; Drug Resistance, | 2012 |
[Use of levofloxacin in the hospital].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Cross Infec | 2003 |
Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use.
Topics: Case-Control Studies; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; D | 2004 |
[Observational study investigating the use of levofloxacin in ICU patients].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Arrhythmias, Cardiac; B | 2004 |
Levofloxacin: a suitable option for the infectious disease consultant.
Topics: Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Cross Infection; Humans; Intensive C | 2004 |
In vitro activity of levofloxacin against recent Gram-negative nosocomial pathogens.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cross Infection; Gram- | 2005 |
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.
Topics: Anti-Bacterial Agents; Case-Control Studies; Cause of Death; Clindamycin; Clostridioides difficile; | 2005 |
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
Topics: Aminoglycosides; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ca | 2005 |
Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Escherichia coli; Fluo | 2006 |
Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Case-Control Studies; Ciprofloxacin; Cross Infection | 2006 |
Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.
Topics: Academic Medical Centers; Case-Control Studies; Cohort Studies; Cross Infection; Drug Resistance, Ba | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Dr | 2006 |
Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Cross I | 2007 |
Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: usefulness of universal urine antigen testing and early levofloxacin therapy.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Bacterial; Cancer Care Facilities; Cross Infection; Female | 2007 |
Is it Clostridium difficile infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea.
Topics: Aged; Analysis of Variance; Case-Control Studies; Cefazolin; Ceftriaxone; Clostridioides difficile; | 2007 |
A pharmacodynamic simulation to assess tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics.
Topics: Anti-Bacterial Agents; Cross Infection; Humans; Imipenem; Levofloxacin; Microbial Sensitivity Tests; | 2008 |
Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Child, Preschool; Cross Infection; | 2008 |
Occurrence of qnr-positive clinical isolates in Klebsiella pneumoniae producing ESBL or AmpC-type beta-lactamase from five pediatric hospitals in China.
Topics: Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Child; Child, Preschool; China; Ciprofl | 2008 |
Comparison of simple methods of methicillin-resistance detection and evaluation of some properties of methicillin-resistant Staphylococcus aureus strains.
Topics: Ciprofloxacin; Cross Infection; Evaluation Studies as Topic; Gentamicins; Humans; Methicillin Resist | 1993 |
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
Topics: Anti-Infective Agents; Cancer Care Facilities; Cross Infection; Drug Resistance, Microbial; Drug Uti | 1994 |
An audit of ciprofloxacin use in a district general hospital.
Topics: Anti-Infective Agents; Bacterial Infections; Cephalosporins; Ciprofloxacin; Cross Infection; Drug Ut | 1995 |
Fluoroquinolone resistance patterns after formulary addition of ofloxacin. A clinical isolate study.
Topics: Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Formularies, Hosp | 1995 |
Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
Topics: Aminoglycosides; Ampicillin Resistance; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Cipr | 1995 |
Molecular characterization of epidemic multiresistant Staphylococcus haemolyticus isolates.
Topics: Ampicillin; Anti-Bacterial Agents; Cefazolin; Cefmetazole; Cross Infection; DNA Restriction Enzymes; | 1998 |
Rhodococcus equi nosocomial meningitis cured by levofloxacin and shunt removal.
Topics: Actinomycetales Infections; Anti-Infective Agents; Cross Infection; Female; Humans; Levofloxacin; Me | 2000 |
Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Cross Infection; Drug | 2000 |
Aspiration pneumonia.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Community-Acquired Infections; Cross Infection; Humans; | 2001 |
Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Chi-Square Distribution; Confiden | 2002 |
[In vitro activity of various antibiotic agents against gram-negative nosocomial bacteremia pathogens].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cross Infection; Gram-Negative Bacteria; | 1992 |
Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bacterial Infections; Cross Infection; Female; | 1992 |
Ofloxacin in lower respiratory tract infections.
Topics: Bacterial Infections; Bronchitis; Chronic Disease; Cross Infection; Drug Administration Schedule; Dr | 1991 |
[In vitro activity, serum, urine and prostatic adenoma concentrations of ofloxacin in urologic patients with complicated urinary tract infections].
Topics: Aged; Anti-Infective Agents, Urinary; Bacteria; Cross Infection; Dose-Response Relationship, Drug; F | 1986 |
[Susceptibilities of clinical isolates to antibacterial agents. Focusing mainly on ofloxacin (first report). Reported by the Research Group for Testing Ofloxacin Susceptibility of Clinical Isolates].
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Drug Resistance, Microbial; | 1988 |
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship, | 1986 |